ストックスクリーナーアプリを入手
122.05
1.89%
2.26
アフターアワーズ：
122.10
0.05
+0.04%
前日終値:
$119.79
開ける：
$119.82
24時間の取引高:
8.19M
Relative Volume:
1.20
時価総額：
$151.44B
収益：
$29.04B
当期純損益:
$8.11B
株価収益率:
18.92
EPS:
6.4525
ネットキャッシュフロー:
$9.67B
1週間 パフォーマンス:
+1.31%
1か月 パフォーマンス:
+8.31%
6か月 パフォーマンス:
+17.72%
1年 パフォーマンス:
+36.35%
1日の値動き範囲:
$119.10
$122.31
1週間の範囲:
$114.02
$122.31
52週間の値動き範囲:
$86.08
$124.61
Gilead Sciences Inc Stock (GILD) Company Profile
GILD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
122.05 | 148.78B | 29.04B | 8.11B | 9.67B | 6.4525 |
|
LLY
Lilly Eli Co
|
896.53 | 772.28B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.26 | 455.04B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
211.96 | 385.18B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
123.86 | 237.53B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
82.49 | 214.76B | 63.99B | 19.05B | 14.72B | 7.5596 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Real time alert setup for Gilead Sciences Inc. performance2025 Top Decliners & Step-by-Step Swing Trade Plans - newser.com
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025 - The Joplin Globe
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting - GlobeNewswire Inc.
Bernstein reiterates Gilead stock rating at Outperform on strong HIV core - Investing.com Nigeria
iA Global Asset Management Inc. Acquires 6,297 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stake Decreased by Hunter Associates Investment Management LLC - MarketBeat
2,128 Shares in Gilead Sciences, Inc. $GILD Purchased by Elm Partners Management LLC - MarketBeat
Spire Wealth Management Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
What candlestick patterns are forming on Gilead Sciences Inc.Trade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Is Gilead Sciences Inc. stock cheap at current valuationJobs Report & Accurate Technical Buy Alerts - newser.com
Longbow Finance SA Purchases 9,390 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Syverson Strege & Co Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
NWK Group Inc. Has $7.33 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Assetmark Inc. - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2025 Earnings Call Transcript - Insider Monkey
Gilead Sciences, Inc. (GILD) Analyst insights, Price targets and Recommendations - Yahoo! Finance Australia
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $105.00 at Royal Bank Of Canada - MarketBeat
Gilead Sciences' (GILD) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Morgan Stanley Boosts Gilead Sciences (NASDAQ:GILD) Price Target to $147.00 - MarketBeat
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $145.00 - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Plans $0.79 Quarterly Dividend - MarketBeat
Gilead Sciences (NASDAQ:GILD) Given New $110.00 Price Target at The Goldman Sachs Group - MarketBeat
Gilead Sciences (NASDAQ:GILD) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Wells Fargo Maintains Gilead Sciences (GILD) Overweight Recommendation - Nasdaq
Fisher Funds Management LTD Reduces Position in Gilead Sciences, Inc. $GILD - MarketBeat
Atria Investments Inc Purchases 14,392 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Price momentum metrics for Gilead Sciences Inc. explainedTrade Analysis Report & Proven Capital Preservation Methods - newser.com
JP Morgan Raises Gilead Sciences (GILD) Price Target to $150 | G - GuruFocus
Gilead Sciences (NASDAQ:GILD) Posts Quarterly Earnings Results - MarketBeat
Gilead Sciences (GILD) Profit Margin Surge Reinforces Bullish Narratives on Operational Turnaround - Yahoo Finance
Needham Reiterates Gilead Sciences (GILD) Buy Recommendation - Nasdaq
Gilead Sciences (NASDAQ:GILD) Updates FY 2025 Earnings Guidance - MarketBeat
Gilead Stock Reverses; Why Its New HIV Shot Looks Better - Investor's Business Daily
Research Alert: CFRA Keeps Buy Rating On Shares Of Gilead Sciences, Inc. - 富途牛牛
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026 - Benzinga
RBC Capital Maintains Gilead Sciences (GILD) Rating, Raises Pric - GuruFocus
Gilead’s long-acting PrEP Yeztugo takes off while cell therapy declines continue to haunt sales - Fierce Pharma
Gilead Sciences: Strong Performance and Future Potential Drive Buy Rating - TipRanks
Gilead's Cell Therapy Portfolio Slumps in Q3, but Firm Still Optimistic About In Vivo Opportunities - Precision Medicine Online
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow - TradingView
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead - Enidnews.com
Does Gilead Sciences Offer Strong Value After Breakthroughs in Antiviral Treatments? - simplywall.st
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir) - BioSpace
Gilead GILD Q3 2025 Earnings Call Transcript - AOL.com
Gilead Sciences (GILD) Maintains Dividend, Adjusts 2025 Outlook - GuruFocus
Gilead Sciences (GILD) Acquires Key Assets from HOOKIPA Pharma - GuruFocus
Hookipa Pharma Completes Sales of HBV and HIV Assets to Gilead Sciences - MarketScreener
Gilead 3rd-qtr EPS beats expectations - The Pharma Letter
GILD Receives 'Buy' Rating Reiteration from Needham | GILD Stock News - GuruFocus
GILD Q3 Deep Dive: HIV and Liver Disease Strength Offset Oncology Headwinds - Yahoo Finance
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
0.71%
0.04%
大文字化:
|
ボリューム (24 時間):